NDC product
diclofenac epolamine
NDC 0093-3727 · Teva Pharmaceuticals USA Inc.
Key facts
| Product NDC | 0093-3727 |
|---|---|
| Proprietary name | diclofenac epolamine |
| Nonproprietary name | diclofenac epolamine |
| Substances | DICLOFENAC EPOLAMINE |
| Dosage form | SYSTEM |
| Route | TOPICAL |
| Labeler | Teva Pharmaceuticals USA Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Application number | NDA021234 |
| Pharmacologic classes | Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Decreased Prostaglandin Production [PE], Nonsteroidal Anti-inflammatory Drug [EPC] |
| Marketing start | May 1, 2020 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: